DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.14
+0.73%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.3x
Market Cap
$947.49M
MomentumView details →
1D Return
+0.73%
YTD Return
+62.35%
RSI (14)
57.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.3x
Market Cap
$947.49M
RSI (14)
57.0
MomentumView details →
1D Return
+0.73%
YTD Return
+62.35%
SummaryUpdated Jun 1, 2026
Design Therapeutics, Inc. (NASDAQ:DSGN) is a preclinical-stage biopharmaceutical company founded in 2017 and headquartered in Carlsbad, California. The company went public in March 2021 and focuses on developing innovative therapies for genetic diseases caused by nucleotide repeat expansions. Design Therapeutics has built a proprietary platform called GeneTAC to create small molecule drugs that can precisely modulate gene expression, targeting a class of previously undruggable genetic disorders that affect millions of patients worldwide.
Similar companies
Latest newsMore news →
Design Therapeutics, Inc. reported a net loss of $20.2 million for Q2 2026, with research and development expenses of $16.4 million and general and administrative expenses of $5.8 million.33d agoDesign Therapeutics initiated patient dosing in a Phase 1 multiple-ascending dose trial of DT-818 for myotonic dystrophy type-1.67d ago